Atalanta Therapeutics

54 people · 0 jobs
‌

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing the proprietary RNA interference platform.

Employees

11-50

Links


Org chart

Aimee L. Jackson
Chief Scientific Officer
Morgan Molloy
Chief Corporate Development Officer
Craig Mello
Co-founder
Jeff Young
Chief Financial Officer
Serena Hung
Chief Medical Officer
Antonio N.
Sr. Director Information Technology

Board & advisors

Neil Aronin
Co-founder & Scientific Advisor
Anastasia Khvorova
Co-founder & Scientific Advisor
Craig Mello
Co-founder & Scientific Advisor
Jim Glasheen
Co-founder